Resources

Trial assesses if link exists between severe hypoglycemia and adverse cardiovascular outcomes in veterans.

Low levels thought to contribute to pathogenesis of painful diabetic peripheral neuropathy due to action on dorsal root ganglia.

Personalized messages based on motivational interviewing principles compared to usual care to determine if any significant difference in self-management of type 2 diabetes.

When is the HbA1c not reliable?

A. Recent blood transfusion
B. Renal failure
C. Medication use (e.g. aspirin)
D. G6PD deficiency
E. All of the above

Follow the link for the answer.

How do you choose the best, affordable treatment for each patient from 6 Million possible combinations for your patients with type 2?

Diabetes in Control is working with an endocrinologist and computer specialist who have developed a program to help you in deciding the best treatment option to manage blood glucose that the patient can afford using their insurance. They are looking for medical professionals to use it and provide feedback.

Would you be interested in learning about a free software that can go through 6 million possible drug combinations for patients with type 2, providing the best options for treatment using the patient’s medical information and insurance? It will rate each combination as to how much it could lower A1c, and provide the cost for each treatment, plus any side effects and even coupons, if available, for the patient to use. This program has already been used for hundreds of patients. See the software in action in a 9 minute video.

If you're interested in trying the software, email me at publisher@diabetesincontrol.com.

Follow the link to share your opinion or request more info.

I have a patient who has type 2 diabetes. He was started on long-acting insulin 8 months ago. Before adding the insulin, he was taking a daily GLP-1. He had experienced diabetic ketoacidosis (DKA) while on a SGLT-2, and did not tolerate metformin due to GI side effects. Therefore, these …

Rachele Berria MD, PhD is Vice President and Head, Diabetes Medical Unit at Sanofi, Bridgewater, New Jersey. She has a medical degree (undergrad/graduate combined program) and Obstetrics and Gynecology Board Certification from the University of Cagliari School of Medicine, Italy. Her many other educational accomplishments include a Master of Science in Clinical Investigation from the University of Texas Health Science Center at San Antonio, Texas; Ph.D. Degree in Medical Pathophysiology and Pharmacology from the University of Pisa School of Medicine, Italy; a Fellowship in Diabetes and Metabolism from the Internal Medicine Department, University of Texas Health Science Center at San Antonio, Texas;  and a Master Practitioner Certification in Effective Communication from the Neurolinguistic Programming Center of New York City, NY.

 In this week’s Homerun Slides, the breakdown of the different CGM categories. To download the complete set in PowerPoint format, just use this link: New CGM Categories and Technologies Part 2. Catch up on past Homerun Slides for New CGM Categories and Technologies: New CGM Categories and Technologies Part 1.

Genetic predisposition is an important component of the multifactorial pathogenesis of T1DM. Although often diagnosed in individuals with no known family history of T1DM, the disease is about 15 times more common in siblings of a patient than in the general population. Siblings have an average risk of 6%, although individual risk varies significantly in relation to the extent of sharing predisposing genes with the proband, which allele variants are shared, and other factors. The risk to the offspring of affected mothers and fathers is about 2–3% and 6–7%, respectively. Among twins, the observed disease concordance rates are approximately 8–10% in dizygotic twins and, with extended follow-up, more than 60% in monozygotic twins.

In this Exclusive Interview transcript, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins, and what Sanofi has in the pipeline.